

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 1

MIRA INFORM REPORT

Report No. :	522239
Report Date :	25.07.2018

IDENTIFICATION DETAILS

Name :	SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED
Formerly Known As :	SINOBRIGHT PHARMACEUTICAL (HONGKONG) CO. LTD.
Registered Office :	C/O SBC Corporate Services Ltd., Room D, 10/F., Tower A, Billion Centre, 1 Wang Kwong Road, Kowloon Bay, Kowloon
Country :	Hong Kong
Date of Incorporation :	10.09.2012
Com. Reg. No.:	60338132
Legal Form :	Private Limited Liability Company
Line of Business :	The subject is a pharmaceutical trader.
No. of Employees :	The subject has no employees in Hong Kong. NOTE: It is to be noted that the company does not have its own operating office in Hong Kong. The company uses the address of its secretariat as its correspondence address only. Subject operates from some other country and does not have a base in Hong Kong. Such companies are registered in Hong Kong just to tax benefit purpose and due to the strict privacy laws prevailing in the country. In such cases, the companies are not required to have any employees in Hong Kong nor do have an office there.

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

ECGC Country Risk Classification List

Country Name	Previous Rating	Current Rating
--------------	-----------------	----------------

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 2

	(31.12.2017)	(01.04.2018)
Hong Kong	A1	A1

Risk Category	ECGC Classification
Insignificant	A1
Low Risk	A2
Moderately Low Risk	B1
Moderate Risk	B2
Moderately High Risk	C1
High Risk	C2
Very High Risk	D

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 52239 (PRELIMINARY REPORT)

PAGE NO. : 3

HONG KONG - ECONOMIC OVERVIEW

Hong Kong has a free market economy, highly dependent on international trade and finance - the value of goods and services trade, including the sizable share of reexports, is about four times GDP. Hong Kong has no tariffs on imported goods, and it levies excise duties on only four commodities, whether imported or produced locally: hard alcohol, tobacco, hydrocarbon oil, and methyl alcohol. There are no quotas or dumping laws. Hong Kong continues to link its currency closely to the US dollar, maintaining an arrangement established in 1983.

Excess liquidity, low interest rates and a tight housing supply have caused Hong Kong property prices to rise rapidly. The lower and middle-income segments of the population increasingly find housing unaffordable.

Hong Kong's open economy has left it exposed to the global economic situation. Its continued reliance on foreign trade and investment makes it vulnerable to renewed global financial market volatility or a slowdown in the global economy.

The mainland has long been Hong Kong's largest trading partner, accounting for about half of Hong Kong's total trade by value. Hong Kong's natural resources are limited, and food and raw materials must be imported. As a result of China's easing of travel restrictions, the number of mainland tourists to the territory surged from 4.5 million in 2001 to 47.3 million in 2014, outnumbering visitors from all other countries combined. After peaking in 2014, overall tourist arrivals dropped 2.5% in 2015 and 4.5% in 2016. The tourism sector rebounded in 2017, with visitor arrivals rising 3.2% to 58.47 million. Travelers from Mainland China totaled 44.45 million, accounting for 76% of the total.

The Hong Kong Government is promoting the Special Administrative Region (SAR) as the preferred business hub for renminbi (RMB) internationalization. Hong Kong residents are allowed to establish RMB-denominated savings accounts, RMB-denominated corporate and Chinese government bonds have been issued in Hong Kong, RMB trade settlement is allowed, and investment schemes such as the Renminbi Qualified Foreign Institutional Investor (RQFII) Program was first launched in Hong Kong. Offshore RMB activities experienced a setback, however, after the People's Bank of China changed the way it set the central parity rate in August 2015. RMB deposits in Hong Kong fell from 1.0 trillion RMB at the end of 2014 to 559 billion RMB at the end of 2017, while RMB trade settlement handled by banks in Hong Kong also shrank from 6.8 trillion RMB in 2015 to 3.9 trillion RMB in 2017.

Hong Kong has also established itself as the premier stock market for Chinese firms seeking to list abroad. In 2015, mainland Chinese companies constituted about 50% of the firms listed on the Hong Kong Stock Exchange and accounted for about 66% of the exchange's market capitalization.

During the past decade, as Hong Kong's manufacturing industry moved to the mainland, its service industry has grown rapidly. In 2014, Hong Kong and China signed a new agreement on achieving basic liberalization of trade in services in Guangdong Province under the Closer Economic Partnership Agreement (CEPA), adopted in 2003 to forge closer ties between Hong Kong and the mainland. The new measures, which took effect in March 2015, cover a negative list and a most-favored treatment provision. On the basis of the Guangdong Agreement, the Agreement on Trade in Services signed in November 2015 further enhanced liberalization, including extending the implementation of the majority of Guangdong pilot liberalization measures to the whole Mainland, reducing the restrictive measures in the negative list, and adding measures in the positive lists for cross-border services as well as cultural and telecommunications services. In June 2017, the Investment Agreement and the Agreement on Economic and Technical Cooperation (Ecotech Agreement) were signed under the framework of CEPA.

Hong Kong's economic integration with the mainland continues to be most evident in the banking and finance sector. Initiatives like the Hong Kong-Shanghai Stock Connect, the Hong Kong- Shenzhen Stock Connect the Mutual Recognition of Funds, and the Bond Connect scheme are all important steps towards opening up the Mainland's capital markets and have reinforced Hong Kong's role as China's leading offshore RMB market. Additional connect schemes such as ETF Connect (for exchange-traded fund products) are also under



MIRA INFORM PRIVATE LIMITED
605, Palmspring, Near D'Mart, Link Road,
Malad (West), Mumbai - 400 064. INDIA
Tel : 91-22-40448000 (44 lines)
Fax : 91-22-40448045 / 40448046
E-mail : mira@mirainform.com
info@mirainform.com
Website : <http://www.mirainform.com>
<http://www.miraglobalcheck.com>
<http://www.miraglobalcollections.com>

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 4

exploration by Hong Kong authorities. In 2017, Chief Executive Carrie LAM announced plans to increase government spending on research and development, education, and technological innovation with the aim of spurring continued economic growth through greater sector diversification.

Source : CIA

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 5

COMPANY NAME

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED

ADDRESS

Registered Office:-

c/o SBC Corporate Services Ltd.

Room D, 10/F., Tower A, Billion Centre, 1 Wang Kwong Road, Kowloon Bay, Kowloon, Hong Kong.

Holding Company:-

Bright Investment Management Ltd., British Virgin Islands.

Associated Companies:-

Shenzhen Sinobright Import & Export Co. Ltd., China.

Sinobright Development Ltd., Hong Kong. [Dissolved]

Sinobright Pharmaceutical Co. Ltd.

503 of Zhongguan Building, Liuxian Road, Xili Town, Nanshan District, 518500 Shenzhen Special Economic Zone, China.

[Tel: 86-755-2651 4150, 2697 4357, 2673 5370

Fax: 86-755-2673 5375

E-mail: yiming@sinobrightpharma.com]

BUSINESS REGISTRATION NUMBER

60338132

COMPANY FILE NUMBER

1798024

DATE OF INCORPORATION

10th September, 2012.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 6

ISSUED SHARE CAPITAL

HK\$1,000,000.00

SHAREHOLDER

(As per registry dated 10-09-2017)

Name

Bright Investment Management Ltd.
Unit 8, 3/F., Qwomar Trading Complex, Blackburne Road, Port Purcell,
Road Town, Tortola, British Virgin Islands.

No. of shares

1,000,000
=====

DIRECTOR

(As per registry dated 10-09-2017)

Name

(Nationality)

MEI Yong

Address

Room 502, Zhong Guan Building, Liu Xian Avenue, Nan Shan
District, Shenzhen, China.

SECRETARY

(As per registry dated 10-09-2017)

Name

SBC Corporate Services Ltd.

Address

Room B, 10/F., Tower A, Billion Centre, 1 Wang
Kwong Road, Kowloon Bay, Kowloon, Hong
Kong.

Co. No.

0618863

HISTORY

The subject was incorporated on 10th September, 2012 as a private limited liability company under the Hong Kong Companies Ordinance.

Originally the subject was registered under the name of Sinobright Pharmaceutical (Hongkong) Co. Ltd., name changed to the present style on 5th February, 2013.

The subject changed its shareholders on 4th October, 2016.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 52239 (PRELIMINARY REPORT)

PAGE NO. : 7

Apart from these, neither material change nor amendment has been ever traced and noted.

GENERAL

Sinobright Pharmaceutical Industries Limited. was incorporated on 10th September, 2012 as a private limited liability company under the Hong Kong Companies Ordinance.

The subject does not have its own operating office. Its registered office is in a commercial service firm located at "Room D, 10/F., Tower A, Billion Centre, 1 Wang Kwong Road, Kowloon Bay, Kowloon, Hong Kong" known as "SBC Corporate Services Ltd." [SBC] which is handling its correspondences and documents. SBC is also the corporate secretary of the subject. "Room D" is the file number of the subject in SBC. SBC has had several offices in Hong Kong.

The subject has no employees in Hong Kong.

According to the Companies Registry of Hong Kong, the subject has issued 1 million ordinary shares of HK\$1.00 each. Formerly 30% were owned by Ms. Mei Ying, 35% owned by Mei Yong, and 35% by Mei Feng. On 4th October, 2016, the three shareholders transferred all their share to Bright Investment Management Ltd. which is a BVI-registered company.

Mr. Mei Yong is the only director of the subject. All the old shareholders belonged to the same Mei family. Mei Yong is a China ID holder and does not have the right to reside in Hong Kong permanently. His registered address is in Shenzhen Special Economic Zone, China. The subject is a pharmaceutical trader.

To our knowledge, the subject has got two associated companies known as Shenzhen Sinobright Import & Export Co. Ltd. and Sinobright Pharmaceutical Co. Ltd. [Sinobright] in Shenzhen Special Economic Zone, China. Both companies are located at the same address.

Also controlled by Mr. Mei Yong and Ms. Mei Ying, Sinobright was founded in 2002. Mr. Mei Yong is the legal representative. Its China phone numbers are 86-755-2697 4357 and 2673 5370.

Sinobright is an export representative for the reputed Chinese pharmaceutical factories, including the products of Gentamycin ex Yantai Justaware Pharma, Erythromycin Thiocyanate ex HEC Biochem, and Metronidazole ex Huanggang Yinhe Aarti Pharma.

Its products are categorised into three divisions:-

- Pharmaceuticals
- Adhesives and Sealants
- Others

Sinobright, the GSP and ISO Certified Pharmaceutical Company and was founded in 1991, is a Professional Import/Export Company on Pharmaceutical APIs, Intermediates, Veterinary drugs, Food and Feed Additives, Fine Chemicals, etc. with good reputation from its customers in India, Vietnam, Southeast Asia, Europe, South America, South Africa, Iran, the Middle East, Brazil, Mexico, etc. 70 to 80% of its products are exported to foreign markets annually.

DISCLAIMER : This Report is **PRIVATE & CONFIDENTIAL** and it is prepared at the request of and for its use by the Subscriber only. The Subscriber shall use the contents of the Report merely as an aid to its business. Mira Inform Private Limited ("MIPL") has collated information/data in the Report, which have not been verified unless otherwise specifically mentioned in the Report. The Subscriber shall independently verify the accuracy and correctness of the information/data before in any way acting upon the same. MIPL shall not be liable for any harm, injury, loss or damage caused to the Subscriber due to default by the Subscriber's debtors/beneficiaries in fulfilling their obligations of any nature whatsoever. This Report or any of its portion shall not be used as a documentary evidence or otherwise before any investigative agencies or forum of law. This Report is confidential and proprietary to MIPL. The Subscriber and/or any other person(s) may not reproduce, publish or disclose any of the contents of the Report to others without the express authorization of MIPL. This Report is prepared and issued to the Subscriber without any risk, responsibility or liability on the part of MIPL or its officials.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 8

The factory of Sinobright is in Zhifu District, Yantai City, Shandong Province, China of which factory area covers about 40,000 sq.m.

Supported by its regular customers, Sinobright is also engaged in development and marketing of niche products which are jointly manufactured by its representative pharmaceutical factories.

Currently, Sinobright has about 30 employees in Shenzhen SEZ, China. Its annual sales turnover range from US\$100 to 150 million. Overall business is normal.

The subject's business in Hong Kong is not active. History in Hong Kong is over five years and three months. Since the subject does not have its own operating office and has no employees in Hong Kong, consider it good for business engagements on L/C basis or in small credit amounts.

NOTE:

It is to be noted that the company does not have its own operating office in Hong Kong. The company uses the address of its secretariat as its correspondence address only. Subject operates from some other country and does not have a base in Hong Kong. Such companies are registered in Hong Kong just to tax benefit purpose and due to the strict privacy laws prevailing in the country. In such cases, the companies are not required to have any employees in Hong Kong nor do have an office there.

SINOBRIGHT PHARMACEUTICAL INDUSTRIES LIMITED - 522239 (PRELIMINARY REPORT)

PAGE NO. : 9

FOREIGN EXCHANGE RATES

Currency	Unit	Indian Rupees
US Dollar	1	INR 69.05
UK Pound	1	INR 90.30
Euro	1	INR 80.54
HKD	1	INR 8.76

Note : Above are approximate rates obtained from sources believed to be correct

INFORMATION DETAILS

Report Prepared by : KET